Molecular structure of β-Catenin/Tcf Inhibitor, FH535, CAS Number: 108409-83-2
β-Catenin/Tcf Inhibitor, FH535 (CAS 108409-83-2)
See product citations (7)
Alternate Names:
N-(2-Methyl-4-nitrophenyl)-2,5-dichlorobenzenesulfonamide
Application:
β-Catenin/Tcf Inhibitor, FH535 is a cell-permeable compound that inhibits Wnt/β-catenin and PPAR
CAS Number:
108409-83-2
Purity:
≥94%
Molecular Weight:
361.20
Molecular Formula:
C13H10Cl2N2O4S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
β-Catenin/Tcf Inhibitor, FH535 is a sulfonamide-based and cell-permeable compound that exhibits a dual pathway inhibition against Wnt/beta-catenin and PPAR. β-Catenin/Tcf Inhibitor, FH535 and its structurally similar analog, PPAR inhibitor GW9662, both exhibit inhibition of coactivator/PPAR binding, though only β-Catenin/Tcf Inhibitor, FH535 blocks beta-catenin/PPAR interaction. Further, the antagonistic activity of β-Catenin/Tcf Inhibitor, FH535 does not involve the covalent modification of non-covalent interaction with the PPR ligand-binding site cysteine residue, which has been experimentally shown to be for GW9662 action. β-Catenin/Tcf Inhibitor, FH535 is an inhibitor of GRIP1, PPAR-β, and PPAR-γ.
β-Catenin/Tcf Inhibitor, FH535 (CAS 108409-83-2) References
- A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. | Handeli, S. and Simon, JA. 2008. Mol Cancer Ther. 7: 521-9. PMID: 18347139
- Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. | Liu, YY., et al. 2010. Mol Cancer. 9: 145. PMID: 20540746
- Evaluation of anti-Wnt/β-catenin signaling agents by pGL4-TOP transfected stable cells with a luciferase reporter system. | Chuang, KA., et al. 2010. Braz J Med Biol Res. 43: 931-41. PMID: 20835687
- Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation. | Zhang, X., et al. 2012. Cancer Sci. 103: 181-90. PMID: 22093097
- Nuclear translocation of β-catenin is essential for glioma cell survival. | Shi, Z., et al. 2012. J Neuroimmune Pharmacol. 7: 892-903. PMID: 22415719
- Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer's disease model via canonical Wnt/β-catenin pathway. | Tiwari, SK., et al. 2014. ACS Nano. 8: 76-103. PMID: 24467380
- EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. | Zhang, J., et al. 2015. Cancer Lett. 356: 929-36. PMID: 25444902
- Canonical Wnt signaling activity in early stages of chick lung development. | Moura, RS., et al. 2014. PLoS One. 9: e112388. PMID: 25460002
- FH535 increases the radiosensitivity and reverses epithelial-to-mesenchymal transition of radioresistant esophageal cancer cell line KYSE-150R. | Su, H., et al. 2015. J Transl Med. 13: 104. PMID: 25888911
- Ehrlichia chaffeensis Exploits Canonical and Noncanonical Host Wnt Signaling Pathways To Stimulate Phagocytosis and Promote Intracellular Survival. | Luo, T., et al. 2015. Infect Immun. 84: 686-700. PMID: 26712203
- Lgr4 is crucial for skin carcinogenesis by regulating MEK/ERK and Wnt/β-catenin signaling pathways. | Xu, P., et al. 2016. Cancer Lett. 383: 161-170. PMID: 27693558
- Rac1 Guides Porf-2 to Wnt Pathway to Mediate Neural Stem Cell Proliferation. | Yang, XT., et al. 2017. Front Mol Neurosci. 10: 172. PMID: 28626389
- Okadaic acid activates Wnt/β-catenin-signaling in human HepaRG cells. | Dietrich, J., et al. 2019. Arch Toxicol. 93: 1927-1939. PMID: 31115591
- Therapeutic normal IgG intravenous immunoglobulin activates Wnt-β-catenin pathway in dendritic cells. | Karnam, A., et al. 2020. Commun Biol. 3: 96. PMID: 32132640
- CTTN Overexpression Confers Cancer Stem Cell-like Properties and Trastuzumab Resistance via DKK-1/WNT Signaling in HER2 Positive Breast Cancer. | Moon, SJ., et al. 2023. Cancers (Basel). 15: PMID: 36831511
Inhibitor of:
β-catenin, δ-catenin, 2610208M17Rik, 9430069J07Rik, ABLIM2, APC, APCDD1, ARHGAP10, ARMC5, Axin, Bcl-9L, beta-catenin, BHLHA9, brachyury 2, C10orf132, C1orf80, C9orf7, cadherin-18, cadherin-29, Cdc34, CELSR2, CELSR3, Centrin-4, Chibby 3, DAAM1, DAPLE, Dapper3, DBC1, DIXDC1, Dmp1, EG245190, FAM123A, FJX1, frizzled-8, GATA-5, GBP8, GRIP1, HEATR5B, HR, HSZFP36, ICAT, Integrin α5, ITF-1, Kremen-2, LEF-1, LIN-44, LOC257407, LOC388963, LOC666145, LOC728804, LRCH3, LRP4, LRP5L, LRP6, LRRFIP1, MAB-5, MIZIP, mPRβ, NKD1, Notum, PCDH11X, PLUNC, POP-1, POP1, PPAR beta, Prickle4, Pygopus 1, R-Spondin3, R-Spondin4, Rab 11A, RFX4, RNF20, RYK, Scratch1, SHISA3, SHKBP1, Soggy-1, SOSTDC1, TCF, TCF-1, TCF-19, TCF-3, TIF1γ, TLE1, TLE2, TLE4, TMEM170B, TMEM88, Vangl1, VPS13C, VRK1, WDR27, WISP-3, Wnt, Wnt-14b, Wnt-15, Wnt-3a, Wnt-6, WTIP, WTX, ZDHHC16, ZNF883, and ZNRF3.Activator of:
BAR-1, BBS3, Dapper1, dishevelled, EG245190, FOXC1, frizzled-2, frizzled-7, Histone cluster 1 H2BD, Histone cluster 1 H2BJ, INTU, Pygopus 2, Rad23B, SENP2, SRGAP1, TMEM170B, WDR5, Wnt-10a, Wnt-10b, Wnt-14, Wnt-2b, and Wnt-8b.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
β-Catenin/Tcf Inhibitor, FH535, 10 mg | sc-221398 | 10 mg | $182.00 | |||
β-Catenin/Tcf Inhibitor, FH535, 50 mg | sc-221398A | 50 mg | $374.00 |